GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Price-to-Tangible-Book

Apogee Therapeutics (Apogee Therapeutics) Price-to-Tangible-Book : 2.96 (As of May. 18, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Price-to-Tangible-Book?

As of today (2024-05-18), Apogee Therapeutics's share price is $50.31. Apogee Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $16.98. Hence, Apogee Therapeutics's Price to Tangible Book Ratio of today is 2.96.

The historical rank and industry rank for Apogee Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

APGE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.04   Med: 2.69   Max: 3.91
Current: 2.96

During the past 2 years, Apogee Therapeutics's highest Price to Tangible Book Ratio was 3.91. The lowest was 2.04. And the median was 2.69.

APGE's Price-to-Tangible-Book is ranked worse than
52.03% of 1230 companies
in the Biotechnology industry
Industry Median: 2.81 vs APGE: 2.96

A closely related ratio is called PB Ratio. As of today, Apogee Therapeutics's share price is $50.31. Apogee Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $16.98. Hence, Apogee Therapeutics's P/B Ratio of today is 2.96.


Apogee Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Apogee Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Price-to-Tangible-Book Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23
Price-to-Tangible-Book
- 2.69

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial - - 2.04 2.69 3.91

Competitive Comparison of Apogee Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Apogee Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apogee Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's Price-to-Tangible-Book falls into.



Apogee Therapeutics Price-to-Tangible-Book Calculation

Apogee Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=50.31/16.984
=2.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Apogee Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Apogee Therapeutics (Apogee Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Executives
Mark C. Mckenna director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson officer: Chief Financial Officer C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr director NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson director, officer: Chief Executive Officer 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener director 3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p. director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski officer: Chief Medical Officer 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453

Apogee Therapeutics (Apogee Therapeutics) Headlines